WO2002094321A1 - Compositions favorisant la guérison d'une fracture osseuse - Google Patents
Compositions favorisant la guérison d'une fracture osseuse Download PDFInfo
- Publication number
- WO2002094321A1 WO2002094321A1 PCT/JP2002/004931 JP0204931W WO02094321A1 WO 2002094321 A1 WO2002094321 A1 WO 2002094321A1 JP 0204931 W JP0204931 W JP 0204931W WO 02094321 A1 WO02094321 A1 WO 02094321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microspheres
- drug
- composition according
- compound
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to a composition for promoting fracture healing, and more particularly, to a pharmaceutical composition containing a PDE 4 inhibitor as an active ingredient; preferably, it is biocompatible and biodegradable with a PDE 4 P inhibitor.
- Fracture refers to a state in which the physiological continuity of bone tissue has been partially or completely cut off, and according to its occurrence, it is classified into (a) fracture due to external force, (b) pathological fracture, and (c) fatigue fracture. Can be.
- the fracture state is indicated by a fracture line (a line following the end of the bone in contact with the fissure caused by the bone dissection), and it includes crack fracture, Wakagi fracture, horizontal fracture, oblique fracture, spiral fracture, segmental fracture, crush fracture, and peeling. It is classified into fractures, compression fractures, collapsed fractures, etc. (Medical Dictionary 18th edition, pp. 719-720, published by Nanzando).
- the healing process of fractures is roughly classified into the following three phases (fracture healing, published in Nankodo April pp. 290-37, pp. 46-51). During the healing phase, which is important for healing, healing is thought to proceed by a different mechanism than bone remodeling, which involves repeated bone formation and osteolysis (bone resorption).
- peptide bioactive substances such as bone morphogenetic protein (BMP) and transforming growth factor (TGF) have been known as substances that promote fracture healing.
- BMP bone morphogenetic protein
- TGF transforming growth factor
- PDE phosphodiesterase
- cAMP cytosolic AMP
- An object of the present invention is to provide a new pharmaceutical composition for promoting fracture healing, which promotes early healing of a fracture.
- Another object of the present invention is to provide a topical composition capable of suppressing the onset of systemic action of a medicinal ingredient by applying topically to a fracture site and efficiently exhibiting only a fracture healing promotion effect at a desired site. It is to provide things.
- Still another object of the present invention is to provide a sustained-release depot preparation for promoting bone fracture healing, in which a medicinal ingredient is gradually released by topical administration, and a single administration can exert a long-term medicinal effect. is there.
- the present invention provides a composition for promoting fracture healing, comprising a PDE4 inhibitor as an active ingredient.
- the present invention particularly provides a composition suitable for topical application to a fracture site, particularly a depot preparation, for promoting fracture healing.
- FIG. 1 is a mimetic diagram of a photograph showing the chondrocyte calcification (calcium deposition) effect of compound number (1) in a culture of rabbit heron chondrocytes.
- FIG. 2 is a graph showing the regeneration status of a defective radius in a heron treated with PDE4P and a harmful agent (compound number (2)) microspheres.
- the upper figure shows the total bone area (mm2), and the lower figure shows Shows the relationship between the bone strength index (SSI: mm3) and the dose of compound (2).
- FIG. 3 is a graph showing the time course of cAMP levels in rat fibula fracture sites treated with PDE4 inhibitor (Compound No. (2)) microspheres.
- FIG. 4 is a graph showing the time course of cAMP levels in the fractured part of the fibula in normal rats and STZ-induced diabetic rats.
- FIG. 5 is a graph showing the in vitro elution characteristics of the microspheres of Example 11 (4), Example 2_ (1), and Example 3- (1).
- FIG. 6 is a graph showing the time course of plasma concentration when compound number (1) was administered intravenously. Data are shown as mean soil standard deviation (number of cases: 3).
- Figure 7 shows the time course of the plasma concentration when the microsphere dispersions obtained in Examples 11 (5), 2 (2) and 3 (2) were injected subcutaneously. It is a graph shown. Data are shown as mean soil standard deviation (number of cases: 5).
- FIG. 8 is a graph showing the change over time of the compound number (1) remaining in the preparation when the microsphere dispersion obtained in Example 2- (2) was injected subcutaneously. Data are shown as the average soil standard deviation (number of cases: 5).
- Figure 9 shows the time course of the compound number (2) remaining in the preparation when the microsphere dispersion obtained in Example 6- (5) and Example 7- (2) was injected subcutaneously. It is a graph shown. Data are shown as mean soil standard deviation (number of cases: 4). BEST MODE FOR CARRYING OUT THE INVENTION
- the composition for promoting fracture healing of the present invention has an excellent effect in the process of healing a fracture, particularly in the repair stage, and replaces a cartilage from a cartilage at a fracture site. It can promote the process of endochondral ossification, which promotes the healing of fractures.
- the pharmaceutical composition of the present invention is prepared by using a PDE 4 inhibitor as an active ingredient and mixing it with a general pharmaceutical excipient or diluent.
- a preferred pharmaceutical composition is a sustained-release composition for topical administration containing PDE4P and a biocompatible and biodegradable polymer.
- the composition for topical administration is preferably in the form of a microsphere, and the microphone mouth sphere may be in the form of an injection.
- the PDE 4 inhibitor used as an active ingredient includes all compounds having PDE 4 P and harmful activity. 29987, JP-A-9-59255, JP-A-10-226685, European Publication No. 158380, International Publication No. 94/25437, U.S. Patent No. 522
- This PDE 4 inhibitors suitable for bone fracture healing composition of the invention may, Trends Inn - fa 1 - kill force Honoré Sciences (Trends in Pharmacological Sciences) classified according to 1 1 Certificates 150-155 page description Of the PDEs 1 to 5 selected, a selective PDE 4 inhibitor having a stronger inhibitory effect on PDE 4 than other PDEs (PDEs 1 to 3 and 5) is preferable, and an inhibitory effect on PDE 4 Those that are at least 10 times stronger than for PDE are preferred. More preferred are those having an inhibitory effect of 50 times or more, more preferably 100 times or more, of other PDEs.
- Preferred PDE 4 inhibitors are Advances in Cyclic Nucleotide Researcii Volume 10, 69-92. Page [1979 Reiben Press (Raven Press) issue] IC 5 of the measured PDE4 inhibitory activity in accordance with the method described. Is 0.1 1000 nM, preferably 0.110 OnM. More preferably, IC 5 . Is less than 100 nM.
- Specific examples of the selective PDE 4 inhibitor include the compound of the compound number (1) (57) represented by the following structure or a pharmaceutically acceptable salt thereof.
- Compounds having PDE 4P and harmful activity can be classified into the following (A;) to (D) from the viewpoint of chemical structure, and are appropriately selected from them.
- the compounds the compounds (A) and (B) are preferable, and the compound (A) is particularly preferable.
- (A) a compound having a naphthalene skeleton or a partial structure similar thereto [for example, compound numbers (1), (2), (38), (47), (52) to (57)],
- (B) a compound having a 3-cyclopentyloxy-14-methoxyphenyl structure or a partial structure similar thereto [for example, compound numbers (6), (9), (11), (12), (14), (17), (19), (20), (21), (24), (25), (26), (27), (33), (34), (35), (39), (40 ), (44), (49), (50), (51)],
- (C) a compound having a xanthine skeleton or a partial structure similar thereto [for example, compound numbers (5), (7), (28), (29), (30), (31), (32), (36 ), (37), (41), (43), (46)], and
- (D) A compound having a structure other than the above (A;) to (C) [for example, compound numbers (3), (4), (8), (10), (13), (15), (16 ), (18), (22), (23), (4 2), (45), (48)]
- Examples of the compound (A) include compounds represented by the following general formulas (I) to (III) and pharmacologically acceptable salts thereof.
- R 1 and R 2 are the same or different and each represents a hydrogen atom, a hydroxyl group, a cyclo-lower-alkyloxy group, or a lower-alkoxy group which may have a substituent, or Forming a lower alkylenedioxy group
- R 3 may have a substituent, nitrogen-containing heterocyclic 6-membered cyclic group
- one OR 4 and OR 5 may be the same or different and may be protected Represents a good hydroxyl group
- R 1 ′ and R 2 ′ are the same or different and each may be a hydrogen atom or a protected hydroxyl group.
- One of R 3 and R 4 ′ may be a protected hydroxyl group.
- R 1 ′′ and R 2 ′′ are the same or different and each is a hydrogen atom or an optionally protected hydroxy group
- R 31 is an optionally protected hydroxymethyl group
- R 32 is a hydrogen atom, a lower alkyl group or a hydroxymethyl group which may be protected
- R 33 is a lower alkyl group which may have a substituent
- R 41 is a hydroxymethyl group which may be protected
- R 42 represents a protected hydroxymethyl group
- the dotted line represents the presence or absence of a double bond
- R 5 ′′ and R 6 ′′ are the same or different and each represents a hydrogen atom or a protected Represents an amino group, or is bonded at the terminal to each other to form a heterocyclic group which may be substituted with an adjacent nitrogen atom.
- PDE 4P which is an active ingredient of the composition for promoting fracture healing of the present invention, is a compound having a naphthalene skeleton or an isoquinoline skeleton or a pharmaceutically acceptable salt thereof among the compounds of (A).
- the compounds of compound numbers (1) and (2) or a pharmaceutically acceptable salt thereof are particularly preferred.
- the composition for promoting fracture healing of the present invention be administered locally near a fracture site so as to maintain the drug concentration at the fracture site without increasing the systemic blood concentration of the drug. .
- a preferred form of the composition of the present invention is a device which gradually releases the drug by topical administration.
- PO e.g., pellets, gels, matrixes, microspheres, biocompatible and biodegradable polymer aqueous solutions with a sustained release of the drug, solutions at the time of administration, Formulations designed to form a drug when administered to a living body, formulations generally encapsulated in various bases that have been reported for use in the field of orthopedics, etc.).
- pellets examples include long-term sustained-release and raw preparations obtained by compression-molding a drug with a lactic acid-dalicholic acid copolymer fine particle having a terminal carboxyl group esterified with an alcohol and a drug (Japanese Patent Application Laid-Open No. — 1 8 7 7 4 9).
- Gel preparations include, for example, phosphates of hyaluronic acid and polyethylene glycol chemically bound to polyethylene glycol, as described in the Journal of Controlled Release 59 (1999) 77-86. Examples include gel preparations dissolved in a buffer.
- matrix preparations include, for example, a preparation in which a drug is impregnated in a granular substance of collagen or an intact membrane, a preparation in which a drug is added in a granular substance of collagen or in the preparation of a fiber membrane (Japanese Patent Laid-Open No. — 182,499, JP-A-6-3,059,832) and the like.
- a formulation that is slowly released by adding a drug to an aqueous solution of a biodegradable polymer that is biocompatible for example, a formulation that is slowly released by adding a drug to an aqueous solution of sodium hyaluronate is considered.
- Formulations that are designed to form a gel when administered in vivo but administered as a solution include, for example, the Journal 'Oppo' Controlled Release ' 33 (1995) 237-243, a drug product in which a lactate-glycolic acid copolymer and a drug are dissolved in N-methyl-12-pyrrolidone, and a lactic acid-glycolic acid copolymer described in 27 (1993) 139-147.
- Examples of such a preparation include a polymer and a drug containing a polymer that becomes a gel at a dynamic temperature, such as a block copolymer of a polymer and polyethylene glycol, which exists in a solution state at a low temperature.
- Formulations encapsulated in various bases generally reported in the field of orthopedics include, for example, bases (for example, poorly water-soluble biocompatible and biodegradable polymers, polymethinolemethacrylate, hydroxyapatite , Tricalcium phosphate Pharmaceutical products manufactured by mixing drug and drug) with Biomaterials (Bioraaterials), Vol. 21, pp. 2405-2412 (2000), International Journal of Pharmaceutics (International Journal of Pharmaceutics) 20 6 Vol. 1-12 (2000)].
- bases for example, poorly water-soluble biocompatible and biodegradable polymers, polymethinolemethacrylate, hydroxyapatite , Tricalcium phosphate Pharmaceutical products manufactured by mixing drug and drug
- the local administration gradually releases an effective amount of a PDE 4 inhibitor to the site of the damaged fracture.
- the particle size is preferably such that it passes through the injection needle, and the particle size is 0.01 to 150 / zm, especially 0.1 to 100 ⁇ m It is preferable that the above range be able to suppress irritation to the disease site.
- composition for promoting bone fracture healing comprising the PDE 4 P harmful agent of the present invention as an active ingredient is preferably reduced in dose in consideration of local administration near the fracture site.
- the amount of PDE 4 P in the microsphere preparation is preferably 0.0001 to 80% by weight, more preferably 0.001 to 50% by weight / 0 , and still more preferably 0.01 to 50% by weight.
- the dose of PDE4 as an active ingredient is appropriately determined by a physician according to the type of PDE4P used and the harmful agent, body weight, age, symptoms, site of application, etc. it is in the range of sites per lng ⁇ l g.
- the composition for promoting bone fracture healing according to the present invention is prepared from a PDE 4 inhibitor and a pharmacologically acceptable excipient or diluent according to a conventional method. And a biodegradable polymer.
- the poorly water-soluble biocompatible and biodegradable polymer is lg It is a biocompatible and biodegradable polymer that requires 1000 m1 or more of water (25 ° C) to be used.
- hydroxy fatty acid polyester and its derivatives for example, polylactic acid, Polydalicholic acid, polycunic acid, polymalic acid, poly-1] 3-hydroxybutyric acid, ⁇ -force prolactone ring-opening polymer, lactic acid-glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, Block copolymers of polylactic acid and polyethylene glycolone, polyglyconic acid and polyethylene glycol Block copolymers with recohol, block copolymers of lactic acid-glycolic acid copolymer with polyethylene glycol, etc., polymers of alkyl ⁇ -cyanoacrylate (eg, polybutyl-2-cyanoacrylate, etc.), Polyalkylene oxalates (eg, polytrimethylene oxalate, polytetramethylene oxalate, etc.), polyorthoesters, polycarbonates (eg, polyethylene carbonate, polyethylene propylene carbonate
- hydroxy fatty acid polyesters particularly preferred are those having an average molecular weight in the range of 2,000 to about 800,000, more preferably in the range of 2,000 to about 200,000, and most preferably have an average molecular weight in the range of 5,000 to 50,000.
- polyesters of hydroxy fatty acids more preferred are polylactic acid, lactic acid-glycolic acid copolymer, and 2-hydroxybutyric acid-glycolic acid copolymer.
- the molar ratio of lactic acid / glycolic acid in the lactic acid-glycolic acid copolymer is preferably 90 / 10-30 / 70, more preferably 80 / 20-40 / 60, and the 2-hydroxybutyric acid-glycolic acid copolymer
- the molar ratio of 2-hydroxybutyric acid and glycolic acid is preferably 90/10 to 30 to 70, more preferably 80/20 to 40/60.
- the PDE 4 inhibitor In order to make the above-mentioned PDE 4 inhibitor into a depot, it can be appropriately formulated according to its form. If necessary, prior to the formulation, the PDE 4 inhibitor and fine particles may be preliminarily filtered. Is also good.
- any conventional microparticle manufacturing method can be used as appropriate, such as jet mill pulverization, hammer mill pulverization, rotating Pole Mino V ⁇ , vibrating pole Pulverization method of physically pulverizing by mill pulverization, bead mining, shaker mill pulverization, rod mill pulverization, tube mill pulverization, etc., pH adjustment, temperature change, change in solvent composition, etc.
- a so-called crystallization method can be employed in which the crystallization is performed, and the crystallization is carried out, and the crystallization is performed by a method such as centrifugation or filtration.
- microsphere preparation For example, the following method is used to produce a microsphere preparation.
- microspheres may be converted after conversion to the free form using an acid or base. .
- the drug is contained in a solution of a poorly water-soluble biocompatible and biodegradable polymer in an organic solvent having a boiling point lower than that of water and immiscible with water (poorly water-soluble polymer solution), and the organic compound thus obtained is obtained.
- This is a method in which the organic solvent is removed after the O / W emulsion is prepared by dispersing the organic phase in an aqueous phase.
- a method of dissolving and dispersing a drug or an aqueous solution of a drug in an organic solvent solution of a poorly water-soluble biocompatible and biodegradable polymer, dispersing the solution, and gradually adding a curing agent to the solution with stirring to precipitate and solidify For example, JP-A No. 60-67417, U.S. Pat. No. 5,508,381, U.S. Pat. No. 5,886,886, Eur. J. Pharm. Biopharra. 42 (1), Vol. This is performed in the same manner as the method described in the above document.
- Spray drying method A drug that dissolves and disperses a drug in an organic solvent solution of a poorly water-soluble biocompatible and biodegradable polymer, or a drug aqueous solution is dispersed, and this is dried with a spray nozzle using a spray dryer. It is a method of spraying into a room and evaporating the organic solvent in the spray droplets in a very short time.
- the preparation method varies depending on the form of the organic phase, and both can be carried out according to a conventional method.
- Examples of the form of the organic phase include the following.
- the organic phase in any of the above forms can be emulsified by a conventional method, for example, by an intermittent shaking method, a mixing method using a propeller type or a turbine type stirrer, a colloidal Minoli method, a method using a homogenizer, an ultrasonic irradiation method, or the like. Is formed.
- Organic solvents used in these methods include halogenated hydrocarbon solvents (such as methylene chloride, chloroform, carbon tetrachloride, chloroethane, dichloroethane, and trichloroethane), and fatty acid ester solvents (ethyl acetate, butyl acetate). ), Aromatic hydrocarbon solvents (benzene), aliphatic hydrocarbons (n-hexane, n- ⁇ -tantan, cyclohexane, etc.), ketone solvents (methyl methyl ketone, etc.), ether solvents (Getyl ether, diisopropyl ether, methyl isobutyl ether, etc.).
- halogenated hydrocarbon solvents such as methylene chloride, chloroform, carbon tetrachloride, chloroethane, dichloroethane, and trichloroethane
- fatty acid ester solvents ethyl acetate, buty
- an emulsifier such as an anionic surfactant (sodium sodium oleate, sodium stearate, sodium lauryl sulfate, etc.), a nonionic surfactant (polyoxyethylene sorbitan, etc.) is used to stabilize the emulsion.
- a nonionic surfactant polyoxyethylene sorbitan, etc.
- -Fatty acid esters [Tween 80, Tween 60 (Nikko Chemicals) etc.], polyethylene castor oil derivatives [HCO-60, HCO- 50 (Nikko Chemicals)], polybutylpyrrolidone, polybutyl alcohol , Carboxymethylcellulose, methylcellulose, lecithin, gelatin, etc.
- an anionic surfactant sodium sodium oleate, sodium stearate, sodium lauryl sulfate, etc.
- a nonionic surfactant polyoxyethylene sorbitan, etc.
- -Fatty acid esters [Tween 80,
- the above-mentioned OZW emulsion is used. It is preferable to add them to the organic solvent phase when forming the microspheres. In order to obtain a drug product, it is necessary to increase the concentration of the active ingredient in the preparation of the organic phase.In this case, an osmotic pressure regulator is added to the aqueous phase to prevent the active ingredient from flowing into the aqueous phase. (See Japanese Patent No. 2608265). By subjecting the OZW type emulsion obtained as described above to an underwater drying method, the organic solvent contained in the emulsion / reaction is removed to produce microspheres.
- a conventional method such as heating the emulsion system or blowing a gas under reduced pressure or blowing a gas is used.
- a method of distilling the solvent in an open system particularly, JP-B-56-19324, JP-A-63-91325, JP-A-8-151321, JP-A-6-211648), a method of distilling solvent in a closed system (JP-A-9-221418), etc.
- it can also be carried out by a method of extracting and removing a solvent using a large amount of an external aqueous phase (Japanese Patent No. 2582186).
- a solution containing a drug, a biodegradable polymer and a good solvent of the polymer miscible with water (Solvent A: acetone, tetrahydrofuran, etc.) is mixed with a poor solvent of the polymer miscible with Solvent A (Solvent B: water, ethanol, etc.) ) And a poor mixture of the polymer immiscible with solvent A (solvent C: glycerin, etc.) and emulsification by adding it to the polymer solution to form a dispersed phase and a homogeneous mixture to form a continuous phase
- solvent C glycerin, etc.
- microspheres are heated in an aqueous phase to a temperature higher than the boiling point of the organic solvent (Japanese Patent Application Laid-Open No. 2000-239152), or the microspheres are covered with a high-melting-point additive, and then heated and dried (Japanese Patent Application Laid-Open No. No. 221417), it is also possible to remove the organic solvent remaining in the microsphere.
- microspheres obtained in this way are collected by centrifugation, filtration, or a sieve, and the water phase additives and the like adhering to the surface are washed away, and if necessary, to prevent aggregation of the microspheres.
- Sugar or sugar alcohol, inorganic salt, etc. after adding an anti-agglomerating agent such as ratatose, mannitol, or sorbitol, lyophilize.
- a microsphere preparation is used as an injection, in order to improve needle penetration, for example, 15 ⁇ or It is preferable to perform sieving with a diameter smaller than that.
- This organic phase is gradually added to a solvent (dispersion medium) that is immiscible with the above organic solvent, such as silicone oil, liquid paraffin, sesame oil, soybean oil, corn oil, cottonseed oil, coconut oil, linseed oil, etc., with stirring. / Form emulsion is formed. If desired, a surfactant may be added to the dispersion medium. The emulsion is cooled to solidify the poorly water-soluble polymer, or is heated to evaporate the solvent in the organic phase to solidify the poorly water-soluble polymer.
- a solvent dispersion medium
- a surfactant may be added to the dispersion medium.
- a hardening agent for example, hexane, hexahedral hexane, methyl ethyl ketone, or otamethylcyclotetracylic hexane, or the like is gradually added to this emulsion under stirring, or the emulsion is gradually added to the hardening agent to form a poorly water-soluble polymer.
- the microspheres are formed by precipitating them.
- microspheres formed in this way are collected by centrifugation, filtration, or a sieve, and the solvent and additives attached to the surface are washed and removed with hexane, purified water, or the like. Freeze dry.
- an anti-agglomeration agent or the like is added, followed by freeze-drying.
- the form of the internal organic phase in the phase separation method includes the following.
- the spray dryer used is a commercial product, for example Palvis 'Mini' spray
- microspheres thus obtained are subjected to a post-treatment in the same manner as those obtained by the underwater drying method to obtain a desired microsphere preparation.
- examples of the water-miscible organic solvent include acetone, methanol, and ethanol, and a mixed solvent thereof.
- Volatile solvents capable of dissolving the drug as necessary methylene chloride, chloroform). May be added.
- examples of the protective colloid agent include polybutyl alcohol.
- a bone healing composition for promoting bone fracture healing containing the PDE 4 inhibitor of the present invention as an active ingredient is administered near a fracture site using a microsphere, it is preferable to administer it locally. Topical injection or implantation is preferred.
- the microspheres obtained in the present invention are added to an aqueous solution containing a dispersant at 0.0001 to; LOO OmgZm1, preferably 0.0005 to 80 Omg / m1, more preferably 0.001 to It can be prepared by dispersing to a concentration of 500 mg / m 1.
- dispersing agent used examples include polyoxyethylene sorbitan fatty acid esters (Tween 80, Tw.een 60 (manufactured by Nikko Chemicals)), polyethylene castor oil (HCO-60, HCO-50 (manufactured by Nikko Chemicals), etc.)
- Nonionic surfactants examples include cellulose dispersants such as sodium carboxymethylcellulose, and algi And sodium dextran and sodium hyaluronate. These dispersants have the function of improving the dispersibility of the microspheres and stabilizing the elution of the medicinal component, and are usually used in an amount of 0.01 to 2% by weight, preferably 0.05 to 1% by weight. It is added.
- injections may contain, as appropriate, preservatives (methylparaben, propylparaben, benzyl alcohol, chloroptanol, sorbic acid, boric acid, amino acids, polyethylene glycols, etc.), isotonic agents (sodium chloride, glycerin, sorbitol) , Budsugar, mannitol, etc.), H regulator (sodium hydroxide, potassium hydroxide, hydrochloric acid, phosphoric acid, citric acid, oxalic acid, carbonic acid, acetic acid, arginine, lysine, etc.), buffering agent (sodium hydrogen phosphate, Potassium hydrogen phosphate).
- preservatives methylparaben, propylparaben, benzyl alcohol, chloroptanol, sorbic acid, boric acid, amino acids, polyethylene glycols, etc.
- isotonic agents sodium chloride, glycerin, sorbitol
- the injection may further contain a steroid-based anti-inflammatory analgesic and a non-steroid-based anti-inflammatory analgesic as required.
- a steroid-based anti-inflammatory analgesic examples include dexamethasone, triamcinolone, triamcinolone acetonide, halopredone, noramethasone, hydrocortisone, prednisolone, methylprednisolone, betamethasone and the like.
- the nonsteroidal anti-inflammatory analgesic include ibuprofen, ketoprofen, indomethacin, naproxen, piroxicam and the like.
- microspheres containing a PDE 4 inhibitor can be used to prepare the above-mentioned suspensions in the form of a solid preparation containing an anti-agglomeration agent and microspheres and a dispersion_injection and injection for preparation of the suspension before use. It can also be made as an injection kit in which distilled water is combined.
- the solid preparation used in the kit can be prepared by suspending microspheres in an aqueous solution containing an anti-agglomeration agent, followed by freeze-drying, drying under reduced pressure, spray drying, etc., and in particular, freeze-drying. Is preferred.
- anti-agglomeration agents mannitol, sorbitol, ratatose, pudose, xylitol, manoletose, galactose, sucrose, etc.
- a dispersant can be added to the aqueous solution, and a solid agent having good dispersibility can be obtained.
- an injectable kit can be prepared by combining a steroid anti-inflammatory analgesic and a non-steroid anti-inflammatory analgesic together with a dispersant.
- the composition for promoting fracture healing comprising the PDE 4 inhibitor of the present invention as an active ingredient includes various warm-blooded mammals, for example, humans, livestock animals (powders, papaver, higgins, pigs), pet animals (dogs, Cat).
- the indications of the composition for promoting fracture healing comprising the PDE 4 inhibitor of the present invention as an active ingredient include (a) fractures caused by external force, (b) pathological fractures (fractures associated with osteoporosis, osteomalacia For fractures, fractures associated with malignant tumors, fractures associated with multiple myeloma, fractures associated with congenital bone dysplasia, fractures associated with osteocystosis, fractures associated with purulent osteomyelitis, fractures associated with marble disease, and nutritional disorders Accompanying fracture), (c) Fatigue fracture.
- composition for promoting fracture healing comprising the PDE 4 inhibitor of the present invention as an active ingredient includes crack fractures, Wakagi fractures, horizontal fractures, oblique fractures, spiral fractures, segmental fractures, crushed fractures, exfoliated fractures, compression fractures, and depressed fractures. And so on.
- CD CD (SD) IGS rats (Charles River Japan; male; 7 weeks old) were bred for 7 days at room temperature (23 ⁇ 2 ° C.) and humidity (maintained within 40 to 70%). During the breeding period, they were allowed to freely eat a commercial diet (manufactured by Suriental Bio; CE- 2 ).
- the left lower limb of the above rat was shaved, disinfected with 70% aqueous ethanol, exposed the fibula with scissors, and cut the fibula with nail scissors (Natsume Seisakusho; B-17) did.
- the cut surfaces were adjusted with tweezers, and the specimen administration group (1 group: 20 animals) contained the drug prepared in Example 2 (1) containing 0.1 mg or 0.5 mg of compound number (1), respectively.
- the microspheres were placed around the cut site with a spatula and sutured with silk thread.
- the drug-free microspheres prepared in Control Example 11 (1) were placed in a spatula around the cut site by the same amount in the sample non-administration group (group 1: 20) and then sutured with silk thread.
- the removed fibula was measured for bone density and bone mineral density at a fracture site (scanning width 1 mm) using a DXA bone density measuring device (manufactured by Aloka; DCS-600).
- Fibula bone mineral content (mg) As shown in Tables 1 and 2 above, in the group to which the drug-containing microspheres were administered, it was found that the bone density and bone mineral density at the fracture site increased in a drug amount-dependent manner.
- Table 3 shows the measurement results of the bone volume.
- the fibula extracted was subjected to a three-point bending test using a bone strength measuring device (Muromachi Kikai; TK-252C) to measure the bone strength. That is, two points 4 mm apart from the fracture surface were supported at right and left sides, and pressure was applied at 3 mm / min from above the fracture surface to break the test bone. The maximum force required to break the test bone at this time was taken as the breaking strength. The total energy expended before breaking the test bone was defined as the breaking energy.
- Tables 4 and 5 show the measurement results of the breaking energy and the breaking strength, respectively.
- CD (SD) IGS rats (Charles River Japan,-; male; 7 weeks old) were bred for 7 days at room temperature (23.2C) and humidity (50 ⁇ 20%). During the breeding period, they were allowed to freely take a commercially available diet (from Orientanorebio; CE-2). (Fracture healing)
- Example 7 containing 0.004 mg, 0.02 mg, 0.1 mg or 0.5 mg of the compound No. (2), respectively.
- the microspheres were placed around the cut site with a spatula, and sutured with silk thread.
- the drug-free microspheres prepared in Control Example 2 were placed in a spatula around the cut site by the same amount in the non-administered group (1 group: 15 animals), and sutured with silk thread. After suturing, all groups were disinfected with 70% ethanol. Two weeks later, 5 animals per group, and 4 weeks later, 10 animals per group were laparotomized under ether anesthesia, euthanized by exsanguination, and the fibula was excised.
- the removed fibula was measured for bone density and bone mineral density at a fracture site (running width 1 mm) using a DXA bone density measuring device (A-oka; S-600).
- Tables 6 and 7 show the measurement results of bone density and bone mineral density, respectively.
- the fibula extracted was subjected to a three-point bending test using a bone strength measuring device (Muromachi Kikai; TK-152C) to measure the bone strength. That is, two points 4 mm apart from the fracture surface were supported, and pressure was applied at 3 mm / min from the top of the fracture surface to break the test bone. At this time, the total energy consumed until the test bone was fractured was defined as fracture energy. Table 9 shows the measurement results of the breaking energy. Table 9
- the costal cartilage was extracted from a NZ heron (Kitayama Labes; male; 4 weeks of age) and immersed in Hank's balanced salt solution (without canolecum and magnesium; manufactured by Lifetec, hereinafter HBSS).
- the costal cartilage was cut together with the ribs one by one, and after removing fat and muscle, the growth cartilage layer of the costal cartilage was cut off.
- the collected growth cartilage layer was finely chopped with a scalpel (manufactured by Feather), and four egrets were collected in one centrifuge tube.
- HBSS HBSS
- ethylenediaminetetraacetic acid monosodium salt ethylenediaminetetraacetic acid monosodium salt was dissolved at a concentration of 0.1% was added to suspend the growing cartilage layer, followed by stirring at 37 ° C for 20 minutes. After centrifuging the centrifuge tube (1500 rpm, 10 minutes), aspirate the supernatant and add 40 ml of HBSS (pH 7.2) containing trypsin to a concentration of 0.2% to the precipitate in the centrifuge tube. After the suspension, the mixture was stirred at 37 for 1 hour.
- the above chondrocyte suspension was dispensed into 24 wells so that the number of cells per 1 well was 50,000.
- the culture medium of each well was replaced with the above culture medium.
- the medium containing the test compound shown in Table 10 below was added as a sample-containing medium (dimethyl sulfoxide was used as a vehicle). (Containing 1%), the culture medium was replaced.
- a sample-free medium does not contain a test compound (behavior
- the culture medium was replaced with the medium containing the specimen at the same time as the medium containing the specimen. At this time, ascorbic acid phosphate was added to the culture solution to a concentration of 0.2 mM.
- the dissolved 0.1 M hydrochloric acid was filtered through a filter, and then dispensed so as to have a volume of 1 ml / Z.
- Figure 1 shows the results. As is evident from Fig. 1, when cultured in a medium supplemented with the compound number (1) of the PDE4 inhibitor, calcification was clearly observed at the 4th week of culture, confirming that it had an effect of increasing the potassium deposition. Was done.
- Example 7 Microspheres of compound number (2) produced in (1) (compound number (2) of 8 jug or 40 zg ⁇ ) were filled in gelatin capsules (Rikipsgel Co., Ltd. No. 5), and the control was carried out. The microspheres prepared in Example 2 were filled, and the total amount of the microspheres filled in the gelatin capsule was 15 mg.
- Gelatin capsules were placed one by one in the deboned area, and the periosteum was reduced to cover the capsules and sutured.
- the control group received the microspheres produced in the control example similarly encapsulated in gelatin capsules. Muscles and epidermis were also sutured and disinfected. Six weeks after the suture, the egret was euthanized by exsanguination under pentobarbital sodium anesthesia, and the right forearm was removed.
- the proximal end of the resected right forearm was on the shoulder fracture line, and the distal end was 5 mm wrist from the proximal end.
- pQCT Norland Stratech Total bone area (mm 2 )
- SS I bone strength index (SS I: mm 3 ) (Clinical Calcium vol. 10, 35-41, 2000) were measured using XCT-96 OA).
- CD (SD) IGs rats (Charles River Japan, male; 7 weeks old) were bred at room temperature (23 ⁇ 2 ° C) and humidity (55 ⁇ 15%) for 7 days. During the breeding period, they were allowed to freely eat a commercial feed (Oriental Bioservice; CRF-1).
- Mean blood glucose levels ranged from 426.12 to 42 8.23 mg / d1.
- the left lower limb of the above rat was shaved, disinfected with 70% aqueous ethanol, exposed the fibula with scissors, and cut the fibula with nail scissors (Natsume Seisakusho; B-17) .
- the cut surfaces were adjusted with tweezers, and the specimen administration group (1 group: 12 animals) contained the microspheres prepared in Example 7- (1) containing 0.03 mg or 0.1 mg of Compound No. (2), respectively. After putting it around with a spatula, it was sutured with silk thread.
- the sample non-administration group (1 group: 12 animals) the same amount of the drug-free microspheres produced in Control Example 2 was placed with a spatula around the cut site and sutured with silk thread.
- the fibula used for the bone mineral content measurement was measured for bone strength by a three-point bending test using a bone strength measuring device (Muromachi Kikai; TK-252C). That is, two points 4 mm apart from the fracture surface were supported, and pressure was applied from the upper part of the fracture surface by 3 mmZ to break the test bone. At this time, the maximum force required to break the test bone was defined as the breaking strength. The total energy expended until the test bone was broken was defined as the breaking energy. Table 13 shows the results. Table 13
- the gap at the bone cutting site was not filled, but for all doses, the gap in the bone cutting site was filled in the sample-administered group, and bone swelling was observed.
- CD (SD) IGs rats (Charles River Japan; male; 7 weeks old) were bred at room temperature (23 ⁇ 2 ° C) and humidity (55 ⁇ 15%) for 7 days. During the breeding period, they were allowed to freely eat a commercial feed (Oriental Bioservice; CRF-1).
- control group (1 group: 6 animals), the cut surfaces were fitted with tweezers and sutured with silk thread. After suturing, all groups were disinfected with 70% aqueous ethanol. At 0, 3, 7, 14, 28, and 42 days after the suture, one animal from each group was laparotomized under ether anesthesia, euthanized by exsanguination, and the fibula was removed.
- the fractured portion of the excised fibula was cut to a length of 1 cm and stored frozen in liquid nitrogen.
- the bone fragments obtained by the cutting were ground at 180 ° C., and the ground material was suspended by adding 6% trichloroacetic acid (300 ⁇ ), followed by ultrasonic stirring.
- the suspension was centrifuged (1200 rpm, 15 minutes), and the supernatant was extracted with ether to remove the acetic acid at the trichloride, followed by treatment at 75 ° C for 5 minutes to remove the ether from the supernatant. did.
- the amount of cAMP in the supernatant thus obtained was measured using a cAMP EIA system (manufactured by Amasham Pharmacia Biotech).
- Fig. 3 shows the results of measuring the amount of cAMP.
- a moderate increase in cAMP level was observed at the peak on day 7, and then gradually decreased.
- Compound No. (2) administration group
- CD (SD) IGs rats Japanese Charles Ripper; male; 8 weeks old were bred at room temperature (23 ⁇ 2. C) and humidity (55 ⁇ 15%) for 7 days. During the breeding period, they were allowed to freely take a commercial feed (manufactured by Oriental Bioservice; CRF-1).
- a solution prepared by dissolving streptozotocin (STZ; Sigma), which induces diabetes, in citrate saline buffer (pH 4.5) to a concentration of 0.05M was added to the above rats. Intravenous injection was performed to give a mg / kg. One week later, blood was collected from the tail, and the blood glucose level was measured using a blood glucose measurement device (M-S Pma X250, manufactured by Molecular Devices). Based on the measurement results, the groups were divided so that there was no significant difference in the blood glucose level between the groups. The average blood glucose level in each group was between 404.5 and 410.0 Omg / d1.
- the fractured portion of the excised fibula was cut to a length of 1 cm and stored frozen in liquid nitrogen.
- the bone fragments obtained by the cutting were pulverized at 180 ° C, and the pulverized product was suspended by adding 300 ⁇ l of 6% trichloroacetic acid, followed by ultrasonic stirring.
- the suspension was centrifuged (12,000 rpm, 15 minutes), and the supernatant was extracted with ether to remove acetic acid at the trichloride, followed by treatment at 75 ° C for 5 minutes to remove ether from the supernatant.
- the amount of cAMP was measured using a cAMP EIA system (manufactured by Amasham Pharmacia Biotech).
- FIG. 4 shows the change over time in the amount of AMP.
- microspheres were dispersed in a dilute solution of polyoxyethylene sorbitan fatty acid ester (Tween 80: manufactured by Nikko Chemicals), and the particle size distribution was measured using a particle size distribution analyzer SAL D-1100 (manufactured by Shimadzu). The average particle size was calculated. As a result, the average particle size was 57 / im.
- microsphere dispersion is added to a physiological saline solution (dispersion medium) containing the drug so that the drug ratio is 2.5 mg / m 1, and sufficiently stirred with a mixer (Touch mixer MT-51: manufactured by Yamato). Produced.
- the drug content in microspheres and the average particle size were measured in the same manner as in Example 11- (4). As a result, the drug content was 3.70%, and the average particle size was 47.
- microspheres obtained in the above (1) were treated in the same manner as in Example 11- (5) to prepare a microsphere dispersion (drug ratio: 2.5 mg / ml).
- the drug content and the average particle diameter in the microsphere were measured in the same manner as in Example 11 (4). As a result, the drug content was 3.73% and the average particle size was 52.2 jum.
- microsphere obtained in (1) was treated in the same manner as in Example 1- (5) to prepare a microsphere dispersion (drug ratio: 2.5 mg / ml).
- the oil phase is 4 m of 0.25% methylcellulose (Metroze: Shin-Etsu Chemical Co., Ltd.)
- Emulsion (oZw) in which an oil phase was dispersed in an aqueous phase was produced by emulsifying the mixture in addition to 1 and a homogenizer (Polytoron: manufactured by Kinematica) at 25 for 5 minutes.
- a homogenizer Polytoron: manufactured by Kinematica
- Example 1 Microspheres The drug content and the average particle size in the gel were measured. As a result, the drug content was 39.6%, and the average particle size was 33.4 / 2 m.
- This emulsion was poured into a cylindrical closed vessel (inner diameter 110 mm; inner volume 1000 ml) previously filled with 400 ml of purified water, and was mounted on a three-one motor (BL-600; manufactured by HEIDON) with a diameter of 50 mm. Agitating at 25 ° C and 400 rpm with four stirring blades (Propeller R type; manufactured by HEID0N), the cylindrical silicone rubber hollow fiber membrane module (manufactured by Nagayanagi Industry Co., Ltd.) Nitrogen gas was passed through the inside of the hollow fiber to remove methylene chloride from inside the container. The nitrogen gas flow rate at this time was 2 L / min. This operation was performed for one hour.
- NAGASEP M60-1800 cylindrical type having the following specifications was used as the cylindrical type silicone rubber hollow membrane yarn module.
- microsphere suspension to produce From microsphere suspension to produce, and through the filter mesh opening 1 50 ⁇ ⁇ to remove aggregates, and the aqueous phase was removed by suction filtration by a filter having opening 20 Myupaiiota. 2.3 g of microspheres were collected by adding a small amount of purified water to the obtained microspheres and freeze-drying.
- the average particle size was measured in the same manner as in Example 1- (4). As a result, the drug content was 9.9%, and the average particle size was 26.4 / zm. (5)
- the microspheres obtained in (4) above were treated in the same manner as in Example 1- (5) to prepare a microsphere dispersion (drug ratio: 0.1 mg / m 1).
- Example 6- (4) the drug content and the average particle size in the microsphere were measured. As a result, the drug content was 10.1% and the average particle size was 27. ⁇ .
- microspheres obtained in the above (1) were treated in the same manner as in Example 6- (5) to prepare a microsphere dispersion (drug ratio: 0.1 mg / ml).
- O oil phase
- microsphere dispersion was prepared in the same manner as in Example 1- (5).
- Example 1- (4) After the final sampling, the remaining eluate was removed from the test tube, and the amount of drug contained in the remaining microspheres was measured by the method of Example 1- (4).
- the dissolution rate was calculated assuming that the sum of the amount of drug eluted and the amount of drug remaining in the microsphere was 100%.
- the plasma concentration was measured by HPLC (column; Hypersil 5-ODS, diameter 4 mm, length 300 mm, manufactured by GENORESCIENCE, excitation wavelength: 315 nm, emission wavelength: 465 nm).
- Figure 6 shows the results.
- Example 1- (5) After acclimation period of 1 week under conditions of 3 ⁇ 2 ° C, free water and feeding, obtained in Example 1- (5), Example 2- (2), and Example 3- (2)
- the microsphere dispersion was administered subcutaneously at a rate of 2 ml per animal (total drug dose: 5 mgZ rat). After administration of the drug, blood was collected from the jugular vein with a syringe containing heparin over time under ether anesthesia, and plasma was obtained by centrifugation. The compound concentration in plasma was measured in the same manner as in Test Example 2.
- microspheres of the PDE 4 inhibitor resulted in the highest plasma of the PDE 4 inhibitor compared to the case of intravenous injection of a physiological saline solution containing 1,10 parts of the PDE 4 inhibitor and no power (Test Example 2).
- the medium concentration could be suppressed to 1 to 25 of 1Z25: LZ100.
- Figure 7 shows the results.
- microspheres were collected from the administration site.
- 5 ml of acetonitrile containing an internal standard substance was added and dissolved with a homogenizer (Polytoron: Kinematica).
- a homogenizer Polytoron: Kinematica
- Touch mixer MT-51 manufactured by Yamato
- Total drug dose 0.1 mg / rat
- Microspheres were collected from the administration site over time, and 1 Oml of acetonitrile was added and dissolved with a homogenizer (Polytoron: Kinematica). After collecting 3 ml of the supernatant after centrifugation at 3000 rpm for 5 minutes, apply 6 ml of 0.5 M aqueous sodium chloride solution and stir with a mixer (Touch mixer MT-51: manufactured by Yamato).
- the composition for promoting fracture healing of the present invention comprises a PDE4P harmful agent as an active ingredient, and in particular, when administered locally to a fracture site, has no side effect due to the systemic action of the PDE4P harmful agent.
- a composition containing a PDE 4 inhibitor and a biocompatible and biodegradable polymer in the form of a depot is sustained by local injection at the fracture site as an injection, especially in the form of microspheres. The effect can be exhibited effectively, and more excellent effects can be obtained.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002447619A CA2447619A1 (en) | 2001-05-23 | 2002-05-22 | A composition for accelerating bone fracture healing |
EP02771772A EP1389468A4 (en) | 2001-05-23 | 2002-05-22 | COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE |
JP2002591037A JP4510384B2 (ja) | 2001-05-23 | 2002-05-22 | 骨折治癒促進用組成物 |
KR10-2003-7015231A KR20040007596A (ko) | 2001-05-23 | 2002-05-22 | 골절 치료 촉진용 조성물 |
US10/478,709 US20040146561A1 (en) | 2001-05-23 | 2002-05-22 | Compositions for promoting healing of bone fracture |
MXPA03010679A MXPA03010679A (es) | 2001-05-23 | 2002-05-22 | Una composicion para acelerar la cicatrizacion de fractura osea. |
US11/826,921 US7659273B2 (en) | 2001-05-23 | 2007-07-19 | Composition for accelerating bone fracture healing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001154064 | 2001-05-23 | ||
JP2001-154064 | 2001-05-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10478709 A-371-Of-International | 2002-05-22 | ||
US11/826,921 Division US7659273B2 (en) | 2001-05-23 | 2007-07-19 | Composition for accelerating bone fracture healing |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002094321A1 true WO2002094321A1 (fr) | 2002-11-28 |
Family
ID=18998478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004931 WO2002094321A1 (fr) | 2001-05-23 | 2002-05-22 | Compositions favorisant la guérison d'une fracture osseuse |
Country Status (9)
Country | Link |
---|---|
US (2) | US20040146561A1 (ja) |
EP (1) | EP1389468A4 (ja) |
JP (2) | JP4510384B2 (ja) |
KR (1) | KR20040007596A (ja) |
CN (1) | CN1520313A (ja) |
AR (1) | AR033918A1 (ja) |
CA (1) | CA2447619A1 (ja) |
MX (1) | MXPA03010679A (ja) |
WO (1) | WO2002094321A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153859B2 (en) | 2001-08-09 | 2006-12-26 | Tanabe Seiyaku Co., Ltd. | Condensed polycyclic compounds |
WO2007058392A1 (ja) * | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
WO2010082563A1 (ja) * | 2009-01-19 | 2010-07-22 | 第一三共株式会社 | ヘテロ原子を有する環状化合物 |
JPWO2012169518A1 (ja) * | 2011-06-07 | 2015-02-23 | ホソカワミクロン株式会社 | 液状組成物及びそれを用いた化粧料並びに育毛剤 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
US8329761B2 (en) | 2006-02-13 | 2012-12-11 | Eastman Kodak Company | Oil-in-oil emulsions |
WO2008027288A2 (en) | 2006-08-30 | 2008-03-06 | The Trustees Of Columbia University In The City Of New York | Treatment for craniosynostosis by growth factor delivery |
EP2030640B1 (en) * | 2007-08-27 | 2012-01-25 | Arthrex, Inc. | Capsules for delivery of bone marrow aspirate |
US20100291027A1 (en) * | 2009-05-14 | 2010-11-18 | Jason Campbell | Hyaluronic acid (ha) injection vehicle |
US20130028978A1 (en) * | 2009-11-10 | 2013-01-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for wound treatment |
EP2658565A2 (en) * | 2010-12-29 | 2013-11-06 | Imperial Innovations Limited | Methods for improving fracture healing and bone formation |
JP6585583B2 (ja) * | 2014-03-27 | 2019-10-02 | 小川香料株式会社 | 乳化組成物 |
EP3515404B1 (en) * | 2016-10-28 | 2020-03-18 | Spinethera | Pharmaceutical compositions and uses thereof |
KR102587602B1 (ko) | 2022-12-29 | 2023-10-13 | 황만기 | 골절 회복을 촉진하는 조성물의 제조방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0557019A2 (en) * | 1992-02-18 | 1993-08-25 | AT&T Corp. | Improved node for a communication network |
EP0748805A1 (en) * | 1995-06-15 | 1996-12-18 | Tanabe Seiyaku Co., Ltd. | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them |
JPH09169665A (ja) * | 1995-12-21 | 1997-06-30 | Kenichi Miyamoto | 骨粗鬆症治療剤 |
WO1998002827A1 (en) * | 1996-07-12 | 1998-01-22 | Lava, Inc. | Digital video system having a data base of coded data for digital audio and video information |
JPH10158267A (ja) * | 1996-11-29 | 1998-06-16 | Medei Sci Puraningu:Kk | 新規プリン誘導体およびこれを含む医薬組成物 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4193926A (en) | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
JPS5619324A (en) | 1979-07-24 | 1981-02-24 | Asahi Electronics | Wheel passage type anchoring clamp |
US4542025A (en) * | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
JPS6067417A (ja) | 1983-09-24 | 1985-04-17 | Tetsuo Kato | 生体内代謝性マイクロカプセルの製法 |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
GB8406906D0 (en) | 1984-03-16 | 1984-04-18 | Akzo Nv | Benzo-thiazole and benzothiophene derivatives |
DK159431C (da) | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
JPH0720859B2 (ja) | 1985-02-07 | 1995-03-08 | 武田薬品工業株式会社 | マイクロカプセルの製造法 |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5939388A (en) * | 1986-07-01 | 1999-08-17 | Rosen; Vicki A. | Methods of administering BMP-5 compositions |
ATE63553T1 (de) | 1986-08-21 | 1991-06-15 | Pfizer | Chinazolindione und pyridopyrimidindione. |
JPH0725689B2 (ja) | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
US5000886A (en) | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
DE3738228A1 (de) | 1987-11-11 | 1989-05-24 | Hoechst Ag | Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln |
JPH01305929A (ja) | 1988-06-02 | 1989-12-11 | Toshiba Corp | X線診断装置 |
WO1990009783A1 (en) | 1989-02-22 | 1990-09-07 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
GB8913889D0 (en) | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
JP2578001B2 (ja) | 1989-12-11 | 1997-02-05 | 明治製菓株式会社 | 抗痴呆薬 |
GB8929208D0 (en) | 1989-12-27 | 1990-02-28 | Almirall Lab | New xanthine derivatives |
EP0482208B1 (en) | 1990-04-25 | 2000-07-19 | Nissan Chemical Industries Ltd. | Pyridazinone derivative |
US5288496A (en) * | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
EP0460488B1 (en) | 1990-05-30 | 2001-07-11 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
EP0459505B1 (en) | 1990-06-01 | 1996-10-02 | Kyowa Hakko Kogyo Co., Ltd. | Imidazonaphthyridine derivatives |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
YU48420B (sh) | 1991-03-25 | 1998-07-10 | Hoechst Aktiengesellschaft | Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem |
JPH0558882A (ja) | 1991-09-04 | 1993-03-09 | Yoshiaki Kawashima | ナノカプセルの製造法 |
JP3205884B2 (ja) | 1991-10-01 | 2001-09-04 | 武田薬品工業株式会社 | 凝集防止剤をコーティングした徐放性微粒子製剤 |
PH31245A (en) | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
JP3042156B2 (ja) | 1992-02-20 | 2000-05-15 | 田辺製薬株式会社 | ナフタレン誘導体、その製法及びその合成中間体 |
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5214008A (en) * | 1992-04-17 | 1993-05-25 | Guardian Industries Corp. | High visible, low UV and low IR transmittance green glass composition |
DE4223169C1 (de) | 1992-07-10 | 1993-11-25 | Ferring Arzneimittel Gmbh | Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe |
JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
CA2140441C (en) * | 1992-07-28 | 2006-11-21 | Garry Fenton | Inhibitors of c-amp phosphodiesterase and tnf |
JP2911732B2 (ja) | 1992-10-01 | 1999-06-23 | 田辺製薬株式会社 | 徐放性多核マイクロスフェア製剤およびその製法 |
US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
JPH06305983A (ja) | 1993-04-21 | 1994-11-01 | Sangi Co Ltd | 薬剤徐放用製剤 |
US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
GB9309324D0 (en) | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
CA2160928C (en) * | 1993-07-28 | 2005-07-05 | Garry Fenton | Compounds as pde iv and tnf inhibitors |
JPH07101861A (ja) * | 1993-08-10 | 1995-04-18 | Tanabe Seiyaku Co Ltd | 抗喘息薬 |
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
US5502072A (en) * | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
CN1046274C (zh) * | 1993-11-26 | 1999-11-10 | 辉瑞大药厂 | 用作消炎剂的异噁唑啉化合物 |
GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
GB9412383D0 (en) | 1994-06-21 | 1994-08-10 | Celltech Ltd | Chemical compound |
GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
DE69526790T2 (de) | 1994-06-24 | 2003-03-06 | Euro Celtique Sa | Verbindungen zur hemmung von phosphodiesrerase iv |
US5817670A (en) | 1994-08-29 | 1998-10-06 | Yamanouchi Pharmaceutical Co., Ltd. | Naphthyridine derivatives and pharmaceutical compositions thereof |
JP3790567B2 (ja) | 1994-09-30 | 2006-06-28 | 武田薬品工業株式会社 | 徐放剤 |
US5614515A (en) * | 1994-11-17 | 1997-03-25 | University Of Southern California | Lazaroid-based compositions and method for preventing adhesion formation using the same |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
DK0814778T3 (da) * | 1995-03-10 | 2001-09-17 | Roche Diagnostics Gmbh | Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf |
TW332201B (en) * | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
US5910492A (en) | 1995-06-05 | 1999-06-08 | Takeda Chemical Industries, Ltd. | Osteogenic promoting pharmaceutical composition |
JP3033090B2 (ja) * | 1995-06-15 | 2000-04-17 | 田辺製薬株式会社 | ナフタレン誘導体、その製法及びその合成中間体 |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
JPH09110678A (ja) | 1995-10-19 | 1997-04-28 | Tanabe Seiyaku Co Ltd | 被覆マイクロスフェア製剤およびその製法 |
GB9523267D0 (en) | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
JP3191004B2 (ja) | 1995-12-15 | 2001-07-23 | 武田薬品工業株式会社 | マイクロスフェアの製造法 |
JP3765338B2 (ja) | 1995-12-15 | 2006-04-12 | 武田薬品工業株式会社 | 注射用徐放性製剤の製造法 |
CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
GB9603723D0 (en) | 1996-02-22 | 1996-04-24 | Merck & Co Inc | Diphenyl pyridyl derivatives as pde iv inhibitors |
AU707574B2 (en) * | 1995-12-15 | 1999-07-15 | Merck Frosst Canada & Co. | Tri-aryl ethane derivatives as PDE IV inhibitors |
GB9526325D0 (en) | 1995-12-22 | 1996-02-21 | Bp Exploration Operating | Inhibitors |
US6010711A (en) * | 1996-01-26 | 2000-01-04 | University Of Rochester | Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors |
GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
DE19617864A1 (de) * | 1996-04-23 | 1997-10-30 | Schering Ag | Neue chirale Phenyldihydrofuranone |
CA2252501A1 (en) * | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
SK283162B6 (sk) * | 1996-05-20 | 2003-03-04 | Darwin Discovery Limited | Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom |
KR100338610B1 (ko) * | 1996-09-04 | 2002-05-27 | 디. 제이. 우드, 스피겔 알렌 제이 | 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도 |
ID19155A (id) * | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
JP3951395B2 (ja) | 1996-12-13 | 2007-08-01 | 田辺製薬株式会社 | ピリジン誘導体、その製法及びその合成中間体 |
US6214008B1 (en) | 1997-04-16 | 2001-04-10 | White Spot Ag | Biodegradable osteosynthesis implant |
FR2762841B1 (fr) * | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
FR2764514B1 (fr) * | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
JP3240593B2 (ja) | 1998-02-16 | 2001-12-17 | 株式会社高研 | 可溶性コラーゲンパウダーを担体とする医薬徐放剤 |
US6451335B1 (en) * | 1998-07-02 | 2002-09-17 | Euro-Celtique S.A. | Formulations and methods for providing prolonged local anesthesia |
AR028986A1 (es) * | 1999-02-23 | 2003-06-04 | Smithkline Beecham Corp | USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA |
FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
FR2793684B1 (fr) * | 1999-05-17 | 2001-08-10 | Ethypharm Lab Prod Ethiques | Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant |
JP5038568B2 (ja) * | 1999-08-21 | 2012-10-03 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 協力剤の組合せ物 |
US20020015735A1 (en) | 1999-12-22 | 2002-02-07 | Hedden David B. | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
US6348602B1 (en) * | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
JP3718708B2 (ja) | 2000-01-19 | 2005-11-24 | 独立行政法人物質・材料研究機構 | リン酸カルシウム系生体用セラミック焼結体およびその製造方法 |
BR0107862A (pt) * | 2000-01-27 | 2002-11-05 | American Cyanamid Co | Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico |
DE60103976T2 (de) * | 2000-01-31 | 2005-07-21 | Pfizer Products Inc., Groton | Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
KR20020093059A (ko) | 2000-04-24 | 2002-12-12 | 다나베 세이야꾸 가부시키가이샤 | 마이크로스피어 제조 방법 |
US7011776B2 (en) | 2000-04-28 | 2006-03-14 | Tanabe Seiman Co., Ltd. | Method and apparatus for preparing microspheres |
JP2003535148A (ja) * | 2000-06-06 | 2003-11-25 | グラクソ グループ リミテッド | 癌の治療方法 |
EP1308440B1 (en) * | 2000-08-11 | 2009-05-06 | Ono Pharmaceutical Co., Ltd. | Piperidine derivatives and drugs containing these derivatives as the active ingredient |
DE10061137B4 (de) * | 2000-12-07 | 2016-10-06 | Takeda Gmbh | Neue pharmazeutische Zubereitung |
SK8792003A3 (en) * | 2001-01-31 | 2004-09-08 | Pfizer Prod Inc | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes and pharmaceutical composition containing them |
MXPA03006886A (es) * | 2001-01-31 | 2003-11-13 | Pfizer Prod Inc | Derivados amida de acido tiazolilico, oxazolilico, pirrolilico e imidazolilico utiles como inhibidores de las isozimas pde4. |
JP4364179B2 (ja) | 2005-08-15 | 2009-11-11 | 株式会社ソニー・コンピュータエンタテインメント | 描画処理装置および描画処理方法 |
-
2002
- 2002-05-22 MX MXPA03010679A patent/MXPA03010679A/es not_active Application Discontinuation
- 2002-05-22 CN CNA028127331A patent/CN1520313A/zh active Pending
- 2002-05-22 KR KR10-2003-7015231A patent/KR20040007596A/ko not_active Application Discontinuation
- 2002-05-22 JP JP2002591037A patent/JP4510384B2/ja not_active Expired - Fee Related
- 2002-05-22 EP EP02771772A patent/EP1389468A4/en not_active Withdrawn
- 2002-05-22 CA CA002447619A patent/CA2447619A1/en not_active Abandoned
- 2002-05-22 US US10/478,709 patent/US20040146561A1/en not_active Abandoned
- 2002-05-22 WO PCT/JP2002/004931 patent/WO2002094321A1/ja active Application Filing
- 2002-05-23 AR ARP020101912A patent/AR033918A1/es not_active Application Discontinuation
-
2007
- 2007-07-19 US US11/826,921 patent/US7659273B2/en not_active Expired - Fee Related
-
2010
- 2010-02-17 JP JP2010032734A patent/JP2010155849A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0557019A2 (en) * | 1992-02-18 | 1993-08-25 | AT&T Corp. | Improved node for a communication network |
EP0748805A1 (en) * | 1995-06-15 | 1996-12-18 | Tanabe Seiyaku Co., Ltd. | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them |
JPH09169665A (ja) * | 1995-12-21 | 1997-06-30 | Kenichi Miyamoto | 骨粗鬆症治療剤 |
WO1998002827A1 (en) * | 1996-07-12 | 1998-01-22 | Lava, Inc. | Digital video system having a data base of coded data for digital audio and video information |
JPH10158267A (ja) * | 1996-11-29 | 1998-06-16 | Medei Sci Puraningu:Kk | 新規プリン誘導体およびこれを含む医薬組成物 |
Non-Patent Citations (7)
Title |
---|
FRANCISCHI JANETTI N. ET AL.: "Anti-inflammatory and analogestic effects of the phosphodiesterase 4 inhibitor rolipra in a rat model of arthritis", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 399, no. 2-3, 2000, pages 243 - 249, XP002957337 * |
HITOSHI SEZAKI: "Drug delivery system (first print)", 1986, NANKODO CO., LTD., XP002957338 * |
KASUGAI SHOHEI ET AL.: "Anabbolic effects of a phosphodiesterase 4 (PDE4) inhibitor in bone and its possible mechanism", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 79, no. SUPPL. 1, 1999, pages 277, XP002957340 * |
KASUGAI SHOHEI ET AL.: "Potential of PDE4 inhibitors in the treatment of osteopenia", DRUG NEWS AND PERSPECTIVE, vol. 12, no. 9, 1999, pages 529 - 534, XP002957339 * |
KINOSHITA T. ET AL.: "Phosphodiesterase inhibitors pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in nomal mice", BONE, vol. 27, no. 6, 2000, pages 811 - 817, XP002957342 * |
MIYAMOTO KEN-ICHI ET AL.: "Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4", BIOCHEMICAL PHARMACOLOGY, vol. 54, no. 5, 1997, pages 613 - 617, XP000926603 * |
WAKI YOSHIHIKO ET AL.: "Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat oeteopenia models", JPN. J. PHARMACOL., vol. 79, no. 4, 1999, pages 477 - 483, XP002957341 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153859B2 (en) | 2001-08-09 | 2006-12-26 | Tanabe Seiyaku Co., Ltd. | Condensed polycyclic compounds |
US7550476B2 (en) | 2001-08-09 | 2009-06-23 | Mitsubishi Tanabe Pharma Corporation | Condensed polycyclic compounds |
US7550475B2 (en) | 2001-08-09 | 2009-06-23 | Mitsubishi Tanabe Pharma Corporation | Condensed polycyclic compounds |
US7550464B2 (en) | 2001-08-09 | 2009-06-23 | Mitsubishi Tanbe Pharma Corporation | Condensed polycyclic compounds |
WO2007058392A1 (ja) * | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
WO2010082563A1 (ja) * | 2009-01-19 | 2010-07-22 | 第一三共株式会社 | ヘテロ原子を有する環状化合物 |
CN102325754A (zh) * | 2009-01-19 | 2012-01-18 | 第一三共株式会社 | 含杂原子的环状化合物 |
CN102325754B (zh) * | 2009-01-19 | 2014-03-12 | 第一三共株式会社 | 含杂原子的环状化合物 |
US8685981B2 (en) | 2009-01-19 | 2014-04-01 | Daiichi Sankyo Company, Limited | Cyclic compound having hetero atom |
JP5630868B2 (ja) * | 2009-01-19 | 2014-11-26 | 第一三共株式会社 | ヘテロ原子を有する環状化合物 |
JPWO2012169518A1 (ja) * | 2011-06-07 | 2015-02-23 | ホソカワミクロン株式会社 | 液状組成物及びそれを用いた化粧料並びに育毛剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1520313A (zh) | 2004-08-11 |
JP4510384B2 (ja) | 2010-07-21 |
US20080031958A1 (en) | 2008-02-07 |
MXPA03010679A (es) | 2004-03-02 |
US20040146561A1 (en) | 2004-07-29 |
KR20040007596A (ko) | 2004-01-24 |
US7659273B2 (en) | 2010-02-09 |
EP1389468A1 (en) | 2004-02-18 |
JP2010155849A (ja) | 2010-07-15 |
EP1389468A4 (en) | 2007-01-10 |
JPWO2002094321A1 (ja) | 2004-09-02 |
AR033918A1 (es) | 2004-01-07 |
CA2447619A1 (en) | 2002-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7659273B2 (en) | Composition for accelerating bone fracture healing | |
KR100245395B1 (ko) | 장기간의 국소 마취를 제공하는 제형 및 그 방법 | |
JP5112461B2 (ja) | 軟骨疾患修復治療用組成物 | |
AU739384B2 (en) | Prolonged anesthesia in joints and body spaces | |
WO1999012571A1 (fr) | Preparations de nanocapsules destinees au traitement de maladies intra-articulaires | |
US20030125237A1 (en) | Controlled release preparation of insulin and its method | |
CN113876724B (zh) | 一种负载帕瑞昔布、白介素-4和牛血清白蛋白用于骨关节炎治疗的双层微球及其制备方法 | |
Liu et al. | Nanoparticle-based drug delivery system—a target strategy for osteoarthritis treatment | |
JP2009292787A (ja) | 軟骨再生促進剤 | |
AU775685B2 (en) | Prolonged anesthesia in joints and body spaces | |
RU2548722C1 (ru) | Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола | |
CN117715625A (zh) | 用于治疗晶体和非晶体相关急性炎症性关节炎的包含秋水仙碱的关节内注射用剂型 | |
KR20240063866A (ko) | 결정-연관 및 비-결정-연관 급성 관절염의 치료에 사용하기 위한 콜히친을 포함하는 관절내 주사를 위한 투여 형태 | |
WO2023152138A1 (en) | Microspheres for extended release of fenofibrate | |
CN117717524A (zh) | 一种负载精氨酸的白蛋白基缓释微球及其制备方法与应用 | |
HU203479B (en) | Process for microcapsulating trh or analogues | |
JP2003192595A (ja) | 局所投与剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002591037 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002771772 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002308878 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2447619 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/010679 Country of ref document: MX Ref document number: 1020037015231 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10478709 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028127331 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002771772 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |